logo
Products
Services
Resources
Selection Guides
About
mFluor™ Violet 540 Anti-human CD19 Antibody
4G7
The 4G7 monoclonal antibody binds with human CD19, a 95 kD transmembrane protein commonly expressed on the surface of B cells and lymphocytes. CD19 plays a role in essential cellular pathways, for example, the antigen receptor-mediated signaling pathway and B cell receptor signaling pathway. Moreover, in some organisms, it acts to positively regulate phosphatidylinositol 3-kinase activity, is an enhancer of protein kinase B signaling and is involved in the positive regulation of release of sequestered calcium ion into cytosol. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands such as Fyn and PI3-kinase. CD19 is a very popular antibody target, with over 30000 publications in the last decade. CD19 is essential for immunology research, commonly serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to mFluor™ Violet 540 (ex/em = 394/537 nm). It is compatible with the 405 nm laser and 525/50 nm bandpass filter (for example, as in the Miltenyi Biotec MACSQuant Analyzer 16).
product image
CatalogSize
Price
Quantity
10193120100 tests
Price
10193121500 tests
Price
 
Antibody properties

Other namesB4
Clone4G7
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Absorbance (nm)401
Correction factor (260 nm)1.326
Correction factor (280 nm)0.543
Extinction coefficient (cm -1 M -1)
18000
1
Excitation (nm)402
Emission (nm)535
Quantum yield
0.21
1
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 21, 2026